Glioblastoma
Glioblastoma is a deadly disease, but researchers at the MUHC have uncovered a therapy that may change the prognosis for patients.
It’s a diagnosis that can devastate a patient – glioblastoma multiforme. It is an extremely aggressive brain tumor that is resistant to treatment. Radiotherapy, chemotherapy, even extensive attempts to remove the tumor surgically cannot force the cancer into remission, leaving physicians with few options. Despite the emergence of intensive treatment strategies, the median survival of patients with glioblastoma is 16 months and only 3-5% of patients survive longer than 3 years.
We need your help to make this unprecedented therapy available to all.
Glioblastoma and the MUHC
In response to the devastation of glioblastoma, Dr. Bassam Abdulkarim of the Research Institute of the McGill University Health Centre (RI-MUHC) is working with a diverse team of physicians and researchers to discover new therapies for patients diagnosed with glioblastoma. After years of research and development, the MUHC’s Cancer Therapeutics Research Team is proud to have discovered a promising new therapy, called ZR2002. The drug will soon be ready for clinical trials, the first step toward making it available to patients.
Help Us End Cancer
We need your help to bring this discovery from the laboratory to clinical research. This important work will help physicians determine optimal treatment protocols when using ZR2002, giving patients the best possible chance at a positive outcome.
Learn More
For more information, please contact, Edith Bolduc, Associate Director of Development at the MUHC Foundation. 514-843-1543 x 34397, [email protected]